Ottmann, Oliver
Saglio, Giuseppe
Apperley, Jane F.
Arthur, Christopher
Bullorsky, Eduardo
Charbonnier, Aude
Dipersio, John F.
Kantarjian, Hagop
Khoury, Hanna Jean
Kim, Dong-Wook
Healey, Diane
Strauss, Lewis
Cortes, Jorge E.
Article History
Received: 4 April 2018
Accepted: 12 June 2018
First Online: 3 September 2018
Conflict of interest
: O.O. has acted as a consultant, advisor, or speaker for ARIAD, Bristol-Myers Squibb, Celgene, Fusion Pharma, Novartis, Pfizer, Roche, and SUN Pharma. G.S. has acted as a consultant and a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. J.F.A. is an NIHR Senior Investigator and acknowledges the support of the Imperial College NIHR Biomedical Research Centre and has acted as a consultant, speaker, and advisor for ARIAD, Bristol-Myers Squibb, Incyte, Novartis, Pfizer, and SUN Pharma. C.A. has served on advisory boards and acted as a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. E.B. has no disclosures to declare. A.C. has served on advisory boards and has acted as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. J.F.D. has no disclosures to declare. H.K. has served on advisory boards for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. H.J.K. has no disclosures to declare. D.-W.K. has received research funding from and served on an advisory committee for Bristol-Myers Squibb. D.H. and L.S. are employees of Bristol-Myers Squibb. J.C. has served as a consultant to and received research funding from ARIAD, Bristol-Myers Squibb, Novartis, Pfizer, and Teva.